D&D Pharmatech (347850.KQ) will present 48-week results from its Phase 2 trial of a treatment for metabolic dysfunction-associated steatohepatitis, or MASH, in an oral session at a U.S. liver disease conference.
The company said the 48-week results from its U.S. Phase 2 trial of zavopegdutide (DD01) have been selected as a late-breaking abstract (LBA) at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) for the second consecutive year.
According to D&D Pharmatech, the LBA program selects the most academically significant and innovative clinical studies produced after the regular abstract deadline and grants them a presentation slot. Of the 3,000 abstracts submitted last year, 40 were accepted as LBAs and fewer than 20 were given oral presentation slots.
The study will be presented orally on the 8th at the conference, which opens in Denver on the 5th of next month. Professor Mazen Noureddin, a leading global authority on MASH and liver disease who serves as principal investigator for the trial, will present topline 48-week histological data for zavopegdutide. D&D Pharmatech confirmed the drug's safety and efficacy in a clinical study report (CSR) in August, after completing the 48-week Phase 2 trial.
"This presentation will disclose 48-week biopsy results, the most important endpoint in MASH drug development, along with additional clinical analyses," said Lee Seul-ki, chief executive of D&D Pharmatech. "We will do our utmost to translate this oral presentation into a successful licensing-out deal for zavopegdutide."
Founded in 1950, the AASLD is one of the world's most authoritative academic societies devoted to liver disease. Its annual meeting draws more than 8,000 physicians, researchers and industry officials from about 80 countries each year to share the latest treatment guidelines and clinical data on MASH, liver cancer, cirrhosis and other liver conditions.
